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Inducible nitric oxide synthase-derived superoxide contributes to
hypereactivity in small mesenteric arteries from a rat model of
chronic heart failure
1Alyson A. Miller, 1Ian L. Megson & *,1Gillian A. Gray
1Endothelial Cell Biology and Molecular Cardiology Section, Centre for Cardiovascular Science, Department of Biomedical
Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9LD
1 The aims of this study were to (a) determine whether inducible nitric oxide synthase (iNOS) is
expressed in small mesenteric arteries from rats with chronic heart failure (CHF), (b) investigate the
functional significance of this potential source of nitric oxide (NO) on vascular responsiveness and
(c) investigate the role that superoxide plays in modulating vascular function in these arteries.
2 CHF was induced in male Wistar rats by coronary artery ligation (CAL). In sham-operated rats
the ligature was not tied but pulled under the artery. Six weeks after surgery CAL rats had left
ventricular (LV) infarctions and elevated LV end-diastolic pressures.
3 Immunoreactive iNOS was found in endothelial cells, vascular smooth muscle cells and in the
adventitia of small mesenteric arteries from CAL rats but not those from sham-operated rats.
4 Third order mesenteric arteries (300 – 350 mm) were mounted in a small vessel pressure
myograph. Endothelium-intact arteries from CAL rats were more responsive to phenylephrine
(PE) than arteries from sham-operated rats (pD2 value, CAL, 6.2+0.1; sham-operated, 5.9+0.1,
P50.05).
5 Both the selective iNOS inhibitor, N-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride
(1400W; 1076 M) and the superoxide dismutase mimetic, Mn [III] tetrakis [1-methyl-4-pyridyl]
porphyrin, (MnTMPyP; 1074 M) reversed the hyperesponsiveness (pD2 values, 1400W, 5.9+0.1;
MnTMPyP, 5.81+0.1, P50.05). The NOS substrate, L-arginine (1073 M), reduced responsiveness of
endothelium-denuded small mesenteric arteries from CAL rats (P50.01). None of these drugs
altered responses to PE in arteries from sham-operated rats.
6 In summary, this study demonstrates that iNOS is expressed in mesenteric arteries from rats with
CHF. However, instead of generating large quantities of NO, iNOS appears to be generating
superoxide, perhaps because of a deficiency in its substrate, L-arginine. Increased superoxide
generation from iNOS contributes to the hyperesponsive nature of endothelium-intact small
mesenteric arteries from rats with CHF.
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Abbreviations: ANOVA, analysis of variance; CAL, coronary artery ligation; CHF, chronic heart failure; CRC, concentration
response curve; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; LV, left ventricle;
LVEDP, left ventricular end-diastolic pressure; MnTMPyP, Mn [III] tetrakis [1-methyl-4-pyridyl] porphyrin; N-
(3-(Aminomethyl) benzyl) acetamidine dihydrochloride; NO, nitric oxide; PE, phenylephrine; SOD, superoxide
dismutase; VSM, vascular smooth muscle; 1400W, N-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride
Introduction
Endothelium-derived nitric oxide (NO) plays a vital role in the
regulation of vasomotor tone and arterial blood pressure (for
review see Moncada et al., 1991). Evidence is accumulating to
suggest that impaired NO-mediated vasodilatation contributes
to increased peripheral vascular resistance associated with
chronic heart failure (CHF). In clinical and experimental CHF
it has been established that endothelium-dependent relaxation
in response to acetylcholine is impaired (Drexler et al., 1992;
Ramsey & Jones, 1994; Bauersachs et al., 1999). In contrast,
data on basal release of NO in CHF is controversial. Some
studies suggest that basal release of NO is preserved or may
even be enhanced in CHF (Drexler et al., 1992; Habib et al.,
1994; Winlaw et al., 1994), while other studies show that it is
impaired (Elsner et al., 1991; Teerlink et al., 1994). The
aetiology of endothelial dysfunction associated with CHF is
unclear and is likely to be complex.
The inducible isoform of nitric oxide synthase (iNOS) is
expressed in the vasculature in response to inflammatory
cytokines and pathogens (Moncada et al., 1991). Inflamma-
tory cytokines such as tumour necrosis factor-a are elevated
in the plasma of patients with CHF (Katz et al., 1994).
Furthermore, iNOS has been reported by some investigators
to be present in the myocardium (Fukuchi et al., 1998;
Vejlstrup et al., 1998) and skeletal muscle (Adams et al.,
1997) of patients with CHF. The role of iNOS in the
vasculature has not been directly addressed in CHF. It has
been suggested, however, that iNOS may be responsible for
increased basal production of NO in CHF (Carville et al.,
1998).
Irrespective of its source, increased basal production of NO
should counteract compensatory constrictor mechanisms and
thus reduce peripheral vascular resistance. Increased super-
oxide production is associated with CHF (Belch et al., 1991).
Superoxide scavenges NO (Gryglewski et al., 1986), therefore,
a reduction in NO bioavailability may well explain why*Author for correspondence; E-mail: gillian.gray@ed.ac.uk
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peripheral vascular resistance remains elevated in CHF despite
a preserved or enhanced basal release of NO.
The aims of the present study were to determine if iNOS is
expressed in isolated small mesenteric arteries from a rat model
of CHF, to determine the functional significance of this
potential source of NO on vascular responsiveness and to
investigate the role that superoxide plays in modulating
vascular function in these arteries.
Methods
Coronary artery ligation model of CHF
All experiments were carried out in accordance with the
Animals (Scientific Procedures) Act 1986. Myocardial infarc-
tion was induced in 5 week old male Wistar rats (250 – 300 g,
Charles River) by coronary artery ligation (CAL), as
previously described (Pfeer et al., 1979). In brief, rats were
anaesthetized (sodium pentobarbitol; 60 mg kg71, i.p.), the
thoracic cavity was opened and the heart exteriorized. Using a
silk ligature, the left anterior descending coronary artery was
tied. In control sham-operated rats, the ligature was not tied
but pulled through under the coronary artery. After closure of
the chest, animals were allowed to recover and were
maintained on standard chow and water ad libitum.
Six weeks after surgery, rats were anaesthetized (sodium
pentobarbitol; 60 mg kg71, i.p.), the right carotid artery was
isolated and a Millar pressure transducer-tipped catheter (2F,
model SPR 407, Millar Instruments, Inc., Houston, TX,
U.S.A.) introduced into the artery for measurement of arterial
blood pressure. The catheter was then advanced into the left
ventricle (LV) for measurement of left ventricular end-diastolic
pressure (LVEDP) as an index of left ventricular function.
Following exsanguination, the mesenteric bed was excised,
the gut removed and the remaining vascular bed placed into
cold, oxygenated (95% O2, 5% CO2), Krebs-Henseleit solution
(composition, in mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4
1.2, KH2 PO4 1.2, NaHCO3 25 and glucose 5.5) for functional
studies. Sections of the mesenteric bed from both CAL and
sham-operated rats were placed in 10% neutral phosphate
buered formalin for fixation. The hearts and lungs were
removed and weighed. Hearts were bisected, fixed in formalin
as above for detection of mature collagen in the infarcted zone
and measurement of infarct size.
Immunohistochemistry
Formalin fixed mesenteric arteries from both CAL and sham-
operated rats were processed in ethanol and embedded in
paran wax. Three-mm sections were taken from blocks,
dewaxed in xylene (10 min), rehydrated through a descending
alcohol series (100, 90 and 70% alcohol; 3 min each) and
washed in water (15 min). To expose antigenic sites, arteries
were treated with 0.1% trypsin (diluted in Tris-buered
saline; pH 7.8; 15 min). Arteries were then treated with anti-
iNOS monoclonal antibody for 24 h (48C), washed in
phosphate buered saline (PBS; pH 7.6; 10 min) and treated
with alkaline phosphatase-conjugated goat anti-rabbit IgG
for 30 min (room temperature). To detect iNOS within
arteries, sections were treated with an alkaline phosphatase
substrate and red fuchsin as a chromogen (*20 min).
Negative controls were treated with an antibody of the same
immunoglobulin class but not directed against the iNOS
epitope. Tissues were counterstained with Harris’ haematox-
ylin (BDH, Poole, U.K.).
Measurement of infarct size
Hearts were processed as above and 3 mm sections taken from
paran blocks. After dewaxing and rehydration, hearts were
treated with Van Gieson’s stain for detection of collagen
formation in infarctions. Infarct size was measured in sections
as previously described (Mulder et al., 1998). Sections were
placed under a CCD video camera module (Sony, U.K.)
attached to a microscope with a 620 lens. The endocardial
and epicardial circumferences of the infarcted tissue and of the
LV were determined with image analysis software (Imaging
Associates, U.K.). Infarct size was calculated as a percentage
[endocardial+epicardial circumference of the infarcted LV
(mm)/endocardial+epicardial circumference (mm)] of the
whole LV.
Preparation of arteries from mesenteric bed
Third order branches of the mesenteric artery (*3 mm length,
internal diameter; 300 – 350 mm) were dissected free of the bed
and mounted between two microcannulae in a small vessel
pressure myograph (Living Systems Instrumentation Inc.,
Burlington, U.S.A.). Arteries were constantly superfused with
warm (378C), oxygenated (95% O2, 5% CO2) Krebs-Henseleit
solution. The intraluminal pressure of the vessel was raised to
60 mmHg and maintained at this level with a pressure servo
unit without further intraluminal perfusion. A pressure of
60 mmHg was chosen because it has been estimated that
vessels of this size would experience pressures approximately
50% of mean arterial pressure in vivo (Halpern & Kelley,
1991). Luminal diameter was measured using a video
dimension analyser (Living Systems Instrumentation Inc.,
Burlington, U.S.A.) and a calibrated hand micrometer, when
the optical dimension analyser was unable to detect dierences
in optical density at smaller lumen diameters.
After an equilibration period of 60 min, arteries were
exposed twice in succession, separated by washout, to modified
Krebs-Henseleit solution containing 60 mM KCl (equimolar
replacement of NaCl by KCl) to obtain maximal constriction.
Arteries were then exposed twice to a supramaximal
concentration of phenylephrine (PE; 1075 M). In all arteries
the endothelial integrity was tested by measuring ACh-induced
relaxation (1075 M) of PE-induced tone (1075 M), with
maximal relaxation indicating the presence of an intact
endothelium. In some arteries, the endothelium was removed
by passing an air bubble through the vessel lumen by a method
previously described (Falloon et al., 1993), and successful
denudation verified by loss of ACh-induced relaxation
(1075 M). After sucient washout and re-equilibration,
arteries were constantly superfused in a closed system with a
total volume of 30 ml warm (378C), oxygenated (95% O2, 5%
CO2) Krebs-Henseleit solution. All drugs used throughout this
study were applied to this 30 ml reservoir, removing 1 ml of
Krebs-Henseleit solution and replacing with the drug being
added (as previously described, Mickley et al., 1997).
Responses were recorded 5 min after addition of drug in order
to allow time for responses to reach equilibrium. Four arteries
were isolated from each CAL and sham-operated rat and the
following experiments carried out in a random order.
Experimental protocols
Vascular responsiveness of arteries from coronary artery ligation
and sham-operated rats To assess vascular responsiveness of
small mesenteric arteries from CAL and sham-operated rats to
adrenoceptor stimulation, cumulative concentration response
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curves (CRC) to PE (161079 to 361075 M) were constructed
in endothelium-intact (n=8) and endothelium-denuded (n=6)
arteries. Following completion of CRCs all vessels were re-
peatedly washed and allowed to re-equilibrate before further
experiments.
Eect of iNOS inhibition on vascular responsiveness To
investigate the role of iNOS in modulating vascular respon-
siveness, endothelium-intact mesenteric arteries were exposed
to the iNOS inhibitor, N-(3-(Aminomethyl) benzyl) acetami-
dine dihydrochloride (1400W; 1076 M, n=8) for 30 min prior
to repeating cumulative CRCs to PE (161079 to 361075 M).
At this concentration, 1400W has been shown to inhibit the
activity of iNOS in isolated rat aortic rings treated with
lipopolysaccharide, without modifying the release of NO from
endothelial NOS (eNOS) (Garvey et al., 1997). 1400W was
present in the superfusate throughout the CRC.
Eect of superoxide quenching on vascular responsiveness To
investigate the role that superoxide plays in modulating
vascular responsiveness, endothelium-intact mesenteric arteries
were exposed to the superoxide dismutase (SOD) mimetic, Mn
[III] tetrakis [1-methyl-4-pyridyl] porphyrin (MnTMPyP;
1074 M, n=8) for 30 min prior to repeating cumulative CRCs
to PE (161079 to 361075 M). At a concentration of 1074 M,
MnTMPyP has been shown to protect endothelial-derived NO
from destruction by superoxide in an in vitro model of
oxidative stress (MacKenzie & Martin, 1998). MnTMPyP was
present in the superfusate throughout the CRC.
Eect of combined iNOS inhibition and superoxide quenching on
vascular responsiveness To further investigate the role of
iNOS and superoxide in modulating vascular responsiveness,
endothelium-intact mesenteric arteries were exposed to the
iNOS inhibitor, 1400W (1076 M, n=8) and the SOD mimetic,
MnTMPyP (1074 M, n=8) for 30 min prior to repeating
cumulative CRC’s to PE (161079 to 361075 M). Both drugs
were present in the superfusate throughout the CRC.
Eect of NOS substrate on vascular responsiveness To
investigate the eect of the NOS substrate, L-arginine, on
vascular responsiveness, endothelium-denuded mesenteric
arteries were exposed to a supramaximal concentration (Schott
et al., 1993) of L-arginine (1073 M, n=6) for 30 min prior to
repeating cumulative CRCs to PE (161079 to 361075 M). L-
arginine was present in the superfusate throughout the CRC.
Assessment of endothelium-dependent relaxations in arteries
from coronary artery ligation and sham-operated rats in the
presence and absence of the SOD-mimetic, MnTMPyP To
assess endothelium-dependent relaxations in mesenteric ar-
teries from CAL and sham-operated rats ACh-mediated
relaxations were measured in PE-constricted arteries. A
submaximal concentration of PE (*EC50), as determined
from PE CRCs, was used to induce arterial tone. Cumulative
CRCs to ACh (1610710 to 361076 M, n=7) were then
obtained in the absence and presence of the SOD-mimetic
MnTMPyP (1074 M, n=6).
Materials
Anti-iNOS monoclonal antibodies were obtained from Aniti
Laboratories (Exeter, U.K.) and alkaline phosphatase-con-
jugated goat anti-rabbit IgG from Vector Laboratories
(Peterborough, U.K.). IgG antibodies were purchased from
Vector Laboratories (Peterborough, U.K.). New Fuchsin
Substrate System was purchased from Dako Corporation
(Carpinteria, U.S.A.).
Phenylephrine hydrochloride, acetylcholine chloride and L-
arginine were obtained from Sigma (Poole, U.K.), were diluted
in Krebs-Henseleit solution to give a stock solution of 1071 M
and frozen (7208C) in aliquots until use on day of experiment.
1400W (N-(3-(Aminomethyl) benzyl acetamidine dihy-
drochloride) was obtained from Calbiochem (Nottingham,
U.K.) and subsequently diluted in saline (0.9% NaCl) under
argon to give a stock solution of 1073 M. Aliquots were then
frozen (7208C) and stored under argon. Further dilutions
were made in Krebs-Henseleit solution. MnTMPyP (Mn [III]
tetrakis [1-methyl-4-pyridyl] porphyrin) was obtained from
Alexis (Nottingham, U.K.) and diluted in Krebs-Henseleit
solution immediately prior to experimentation.
Analysis of data
All results were expressed as means+s.e.mean. Where
maximal values were obtained for cumulative CRCs, the
negative logarithm of the agonist concentration that results in
a half-maximal constriction or relaxation (pD2) was calculated.
Two-tailed t-tests, one-way analysis of variance (ANOVA)
with Bonferroni multiple comparisons post-test and two-way
repeated measures ANOVA were used as indicated in the text.
P50.05 was considered to be statistically significant.
Results
Eect of left coronary artery ligation
All the animals that survived the first 24 h after CAL surgery
(76%) were still alive 6 weeks later. There were no significant
dierences between rat weights for CAL and sham-operated
groups at 6 weeks after surgery (Table 1). Heart weights
(corrected for body weight) for CAL rats were significantly
greater than those of sham-operated rats despite the presence
of large infarcts (P50.05, two-tailed unpaired t-test, Table 1),
indicating that hearts from CAL rats had undergone
compensatory hypertrophy as a result of left ventricular
infarction. There were no significant dierences between
groups with respect to lung weights and arterial blood
pressures (Table 1). LVEDPs measured from CAL rats were
significantly greater than those for sham-operated rats
(P50.05, two-tailed unpaired t-test, Table 1). CAL rats had
left ventricular infarctions averaging 60+3% of the LV free
wall. Additionally there was histological evidence for mature
collagen scar formation within the infarcted zone (not shown).
Table 1 Summary of all parameters measured from
coronary artery ligation (CAL) and sham-operated (SHAM)
rats
Parameter
CAL
(n>8)
SHAM
(n>8)
Rat weight (g)
Heart weight (g kg–1 body weight)
Lung weight (g kg–1 body weight)
Left ventricular end-diastolic
Pressure (mmHg)
Arterial pressure (mmHg)
473.9+9.7
3.3+0.2*
4.3+0.5
15.4+1.5**
78.2+5.7
495.7+22.3
2.7+0.1
3.3+0.1
6+1.1
94.8+6.2
All values are given as mean+s.e.mean. *P<0.05,
**P<0.001 for CAL rats compared with sham-operated
rats (two-tailed unpaired t-test).
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Immunohistochemistry
Immunoreactive iNOS was found in endothelial cells, vascular
smooth muscle (VSM) cells and in the adventitia of small
mesenteric arteries from CAL rats (Figure 1). No immunor-
eactivity was found in mesenteric arteries from sham-operated
rats (Figure 1) or in negative controls using IgG antibodies
(not shown).
KCl, PE maximal constrictions and endothelial integrity
There were no significant dierences between endothelium-
intact and endothelium-denuded small mesenteric arteries
from CAL and sham-operated groups with respect to internal
diameters at rest and in response to KCl (60 mM; Table 2).
However, maximal constriction to PE was significantly greater
in endothelium-denuded than in endothelium-intact mesenteric
arteries from both CAL and sham-operated rats (P50.05,
one-way ANOVA with Bonferroni post-test, Table 2). All
endothelium-intact small mesenteric arteries studied had
functional endothelium (CAL, 101.3+4%; sham-operated,
95.9+3% relaxations to ACh) and no significant dierences in
maximal relaxations were found between CAL and sham-
operated groups (Table 2).
Assessment of vascular responsiveness to adrenoceptor
stimulation in coronary artery ligation and
sham-operated rats
In both endothelium-intact and endothelium-denuded small
mesenteric arteries from CAL and sham-operated rats,
cumulative additions of PE (161079 to 361075 M) resulted
in concentration-dependent constrictions (Figure 2a,b). In
endothelium-intact arteries from CAL rats, cumulative CRCs
to PE were shifted significantly to the left when compared with
responses in sham-operated groups, indicating that arteries
from CAL rats were more responsive to PE than those from
sham-operated rats (P50.05, two-way ANOVA, Figure 2a).
Indeed, pD2 values for PE CRCs in arteries from CAL rats
were significantly greater than those in sham-operated rats
(CAL, 6.2+0.1; sham-operated, 5.9+0.1, P50.05, two-tailed
unpaired t-test). There was no significant dierence between
maximal constrictions observed in arteries from CAL and
sham-operated rats (Figure 2a).
In endothelium-denuded arteries no significant dierences
were found between CAL and sham-operated rats with respect
to PE CRCs (Figure 2b). In addition, there were no significant
Figure 1 Localization of iNOS by immunohistochemical staining in mesenteric arteries from coronary artery ligation and sham-
operated rats. (a) Showing immunoreactive iNOS (pink staining) in endothelial cells, vascular smooth muscle cells and in the
adventitia of mesenteric arteries from rats following coronary artery ligation. (b) Showing absence of immunoreactive iNOS in
arteries from sham-operated rats. Nuclei are stained with Harris’ Haematoxylin (purple staining). Magnification 6400, scale
bar=30 mm.
Table 2 Internal luminal diameters of endothelium-intact
(+end) and -denuded (–end) arteries from coronary artery
ligation (CAL) and sham-operated (SHAM) rats
CAL (mm) SHAM (mm)
+end
(n=11)
– end
(n=9)
+end
(n=8)
– end
(n=8)
Resting
60 mM KCl
10–5 M PE
10–5 M ACh
330+9
125+9
120+5**
335+10
310+10
110+10
85+5
95+5
319+15
118+15
117+5*
305+15
310+13
105+10
88+10
107+20
Internal diameters of arteries at rest, after exposure to KCl,
phenylephrine (PE) and acetylcholine (ACh) (arteries pre-
contracted with 10–5 M PE) are given as mean values+s.e.
mean. *P<0.05 as compared with sham-operated endothe-
lium-denuded arteries, **P<0.01 as compared with CAL
endothelium-denuded arteries (one-way ANOVA with
Bonferroni post-test).
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dierences between pD2 values (CAL, 6.3+0.3; sham-
operated, 5.9+0.2) and maximal % constrictions (Figure 2b).
Eect of 1400W and MnTMPyP on vascular
responsiveness
Treatment of endothelium-intact arteries from CAL rats with
1400W (1076 M) or MnTMPyP (1074 M) shifted PE CRCs to
the right with respect to responses in untreated arteries
(P50.05 for both, two-way ANOVA, Figure 3a), indicating
a reduction in responsiveness to PE. pD2 values were
significantly decreased in the presence of 1400W or MnTMPyP
when compared with untreated arteries (untreated, 6.3+0.1;
1400W, 5.9+0.1; MnTMPyP, 5.8+0.1, P50.05, one-way
ANOVA with Bonferroni post-test). Responses to PE in
arteries from CAL rats treated with 1400W or MnTMPyP
were not significantly dierent from those in sham-operated
arteries (Figure 3a). Responses to PE in endothelium-intact
arteries from sham-operated rats were unaected by 1400W
(1076 M) or MnTMPyP (1074 M) (Figure 3b).
In a similar fashion to those arteries treated with 1400W
(1076 M) or MnTMPyP (1074 M) alone, combined treatment
with both drugs resulted in significant reduction in respon-
siveness of arteries from CAL rats to PE (P50.01 two-way
ANOVA, Figure 3a). pD2 values were significantly decreased
in the presence of 1400W and MnTMPyP when compared with
Figure 2 Cumulative concentration response curves (CRC) showing
contractile responses to phenylephrine (PE; 161079 to 361075 M)
in (a) endothelium-intact (n=8) and (b) endothelium-denuded (n=6)
small mesenteric arteries from coronary artery ligation (CAL) and
sham-operated rats 6 weeks post-surgery. Values are given as
means+s.e.mean. *P50.01 as compared with CRCs in sham-
operated arteries (two-way ANOVA).
Figure 3 Eect of 1400W (1076 M) and MnTMPyP (1074 M), on
their own or together on cumulative concentration response curves
(CRC) to phenylephrine (PE; 161079 to 361075 M) in endothe-
lium-intact small mesenteric arteries from (a) coronary artery ligation
(CAL; n=8) and (b) sham-operated (n=8) rats 6 weeks post-surgery.
Values are given as means+s.e.mean. *P50.01 for CRCs in
untreated arteries compared with CRCs in 1400W, MnTMPyP
treated arteries from CAL rats (two-way ANOVA).
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untreated arteries (untreated, 6.3+0.1; 1400W+MnTMPyP,
5.7+0.2, P50.01, one-way ANOVA with Bonferroni post-
test). However, no dierences were found when compared with
responses in arteries treated with 1400W alone. In arteries
from sham-operated rats, combined treatment had no
significant eect on responses to PE (Figure 3b).
Eect of L-arginine on vascular responsiveness
Treatment of endothelium-denuded arteries from CAL rats
with the NOS substrate, L-arginine (1073 M) for 30 min shifted
PE CRCs to the right with respect to untreated arteries
(P50.05, two-way ANOVA, Figure 4a), indicating that in the
presence of L-arginine arteries are less responsive to PE. pD2
values could not be calculated as maximal constrictions were
not reached. L-arginine had no significant eect on PE
responses in arteries from sham-operated rats (Figure 4b).
Endothelium-dependent relaxations: eect of superoxide
quenching
Following induction of PE-induced tone (CAL, 49.1+2.3%;
sham-operated, 52.6+2.4% of maximal PE constriction) in
endothelium-intact arteries from CAL and sham-operated
rats, cumulative additions of ACh (1610710 to 361076 M)
resulted in concentration-dependent relaxations. pD2 values for
cumulative CRCs in arteries from CAL rats were significantly
lower than those in sham-operated rats, indicating that
endothelium-dependent relaxations were blunted in small
mesenteric arteries from CAL rats (CAL, 7.4+0.1; sham-
operated, 7.9+0.2, P50.05, two-tailed unpaired t-test).
Maximum relaxations to ACh were achieved in most arteries
at a concentration of 361076 M and no significant dierences
were found between CAL and sham-operated groups (CAL,
104.1+3.5%; sham-operated, 102.4+2.4%).
In the presence of MnTMPyP (1074 M), relaxations to ACh
in arteries from CAL rats were significantly enhanced, with a
significant increase in pD2 values (untreated 7.4+0.1;
MnTMPyP, 7.9+0.2, P50.05, two-tailed paired t-test).
Treatment of arteries from sham-operated rats with
MnTMPyP had no significant eect on ACh CRCs.
Discussion
The salient finding of this study is that iNOS is expressed in
mesenteric arteries from rats with CHF. However, despite the
presence of iNOS, endothelium-intact small mesenteric arteries
from CHF rats were found to be more responsive to
phenylephrine that those from sham-operated rats. Hyper-
esponsiveness of endothelium-intact arteries from CAL rats
was reversed by the iNOS inhibitor, 1400W and by the SOD-
mimetic, MnTMPyP. Furthermore, supplementation of en-
dothelium-denuded arteries from CAL rats with the NOS
substrate resulted in a significant reduction in responsiveness
to phenylephrine. These results suggest that substrate deficient,
iNOS-derived superoxide may be responsible for the vascular
dysfunction associated with this model of CHF.
Increased cytokine levels may serve as a stimulus for iNOS
expression in CHF (Katz et al., 1994). Indeed, iNOS is
expressed in the myocardium (Fukuchi et al., 1998; Vejlstrup et
al., 1998) and skeletal muscle (Adams et al., 1997) in clinical
CHF. In the present study, iNOS was expressed in endothelial
cells, VSM cells and in the adventitia in small mesenteric
arteries from rats with CHF, but not in arteries from sham-
operated rats. This is the first study to demonstrate iNOS
expression in the peripheral vasculature in experimental CHF.
These findings are in contrast to a recent study, which failed to
detect iNOS in thoracic aortae from rats 8 weeks after
myocardial infarction (Bauersachs et al., 1999). Dierences in
vessel type may explain this discrepancy. Moreover, rats used
in the present study had larger infarcts than those used in the
aforementioned study, perhaps suggesting that the severity of
the model influences iNOS expression.
During endotoxemia, expression of iNOS in the vascula-
ture, and the subsequent production of NO, plays an
important role in the vascular hyporeactivity to vasoconstric-
tors (for review see Thiemermann, 1994). Therefore, in this
model of CHF, increased production of NO from iNOS would
be expected to reduce vascular responsiveness to phenylephr-
ine. Somewhat paradoxically, endothelium-intact small me-
Figure 4 Eect of L-arginine (1073 M) on cumulative concentration
response curves (CRC) to phenylephrine (PE; 161079 to 361075 M)
in endothelium-denuded small mesenteric arteries from (a) coronary
artery ligation (CAL; n=6) and (b) sham-operated (n=6) rats 6
weeks post-surgery. Values are given as means+s.e.mean. *P50.01
as compared with CRCs in untreated arteries (two-way ANOVA).
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senteric arteries from CHF rats were more responsive to
phenylephrine than arteries from sham-operated rats. There
was no significant dierence between responses to phenylephr-
ine in endothelium-denuded arteries from CHF or sham-
operated rats, demonstrating that this vascular dysfunction is
dependent on the presence of the endothelium. Basal NO from
eNOS serves to dampen the eects of vasoconstrictors. One
could speculate, therefore, that decreased basal release of NO
is responsible for the hyperesponsiveness to phenylephrine.
Teerlink et al. (1994) showed increased adrenergic responsive-
ness of thoracic aortic rings from rats with CHF, which was
dependent on the presence of the endothelium. Furthermore,
their study demonstrated that impaired basal release of NO
from the endothelium was responsible for this vascular
dysfunction.
To investigate the role that iNOS plays in modulating
vascular function in this model of CHF we used a novel
selective iNOS inhibitor, 1400W, and the NOS substrate, L-
arginine. 1400W is an irreversible inhibitor of iNOS that is at
least 1000 fold more selective for iNOS than eNOS in rats
(Garvey et al., 1997). Furthermore, 1400W is eective in
abolishing iNOS activity and attenuating hypotension asso-
ciated with endotoxemia in rats (Wray et al., 1998). In the
present study we show, somewhat surprisingly, that inhibition
of iNOS with 1400W reversed, rather than potentiated, the
hyperesponsiveness of small mesenteric arteries from CHF
rats. These results suggest that induction of iNOS does not
result in the expected increase in NO generation. Instead,
expression of the enzyme appears to be a major contributory
factor in the hyperesponsive nature of endothelium-intact
CHF arteries. In experimental endotoxemia addition of the
NOS substrate, L-arginine, to isolated blood vessels increases
NO production from iNOS and potentiates hyporesponsive-
ness to vasoconstrictors (Julou-Schaeer et al., 1990). Here we
show that supplementation of endothelium-denuded small
mesenteric arteries from CHF rats, but not sham-operated
rats, with a supramaximal concentration of L-arginine results
in a reduction in responsiveness to phenylephrine, presumably
through production of NO from iNOS. These results suggest
that although iNOS is present in small mesenteric arteries from
CHF rats, it is unable to synthesize NO because there is
insucient substrate. Recent studies have shown that iNOS,
when deficient in its substrate/cofactors, produces superoxide
rather than NO (Xia & Zweier, 1997; Xia et al., 1998).
Therefore, in this model of CHF, it is possible that a deficiency
in L-arginine will not only prevent iNOS from generating NO
but will also result in the enzyme producing superoxide.
Increased scavenging of NO by superoxide would result in a
reduction in the bioavailability of endothelium-derived NO,
which may explain the marked increase in responsiveness of
endothelium-intact arteries from CHF rats to phenylephrine.
To determine if increased superoxide production plays a
role in modulating vascular function in this model of CHF, we
used the cell permeable metalloporphyrin SOD mimetic,
MnTMPyP. In a similar fashion to 1400W, MnTMPyP
reversed the hyperesponsiveness of endothelium-intact small
mesenteric arteries from CHF rats. This implies that
mesenteric arteries from CHF rats are indeed generating
superoxide, which is responsible for the marked elevation in
responsiveness to phenylephrine. Numerous studies have
demonstrated increased superoxide production in CHF
(McMurray et al., 1990; Belch et al., 1991; Bauersachs et al.,
1999). NADH/NADPH oxidases (Bauersachs et al., 1999),
autoxidation of catecholamines, increased arachidonate
metabolism and inflammatory cytokines have all been
suggested as possible sources of superoxide in CHF (for
review see Givertz & Colucci, 1998). In the present study,
however, both inhibition of iNOS and superoxide quenching
reverses the hyperesponsiveness to phenylephrine suggesting
that iNOS is the source of superoxide in this model of CHF.
Indeed, there were no significant dierences between responses
to phenylephrine in arteries treated with 1400W alone and
those treated with both 1400W and MnTMPyP.
Although MnTMPyP has been shown to protect SOD-null
E. coli against oxidant stress (Faulkner et al., 1994), recent
studies provide evidence that MnTMPyP may actually
scavenge NO itself and directly inhibit the activity of eNOS
(Pfeier et al., 1998; Mackenzie et al., 1999). Mackenzie et al.
demonstrated an augmentation of phenylephrine-induced
constrictions by MnTMPyP in isolated rat aortic rings that is
reversed by inhibition of eNOS. However, in the present study
MnTMPyP reduced responsiveness to phenylephrine in
endothelium-intact small mesenteric arteries from CHF rats
and had no significant eect on responses in arteries from
sham-operated rats. We are convinced, therefore, that the
eects of MnTMPyP in the present study are a direct
consequence of its SOD-mimetic properties.
This study presents an interesting new facet to the impact of
iNOS in CHF. In this model of CHF, instead of generating
large quantities of NO, iNOS appears to be generating
superoxide, perhaps because of a deficiency in its substrate,
L-arginine. Moreover, this increase in superoxide production is
responsible for the hyperesponsive nature of endothelium-
intact small mesenteric arteries from rats with CHF. The
precise mechanism and time course by which superoxide
results in arteries being hyperesponsive is unclear from these
experiments alone. However, the fact that the hypereactivity is
dependent on the endothelium suggests that increased
scavenging of basal, eNOS-derived NO by superoxide is
responsible. In addition to impaired basal release of NO, we
also show that ACh-mediated endothelium-dependent relaxa-
tions are impaired in arteries from rats with CHF. Moreover,
relaxations to ACh were improved in the presence of
MnTMPyP.
In summary, the present study suggests that substrate
deficient, iNOS-derived superoxide is responsible for increased
responsiveness of endothelium-intact mesenteric arteries,
possibly as a result of impaired release of endothelial-derived
NO. While it remains to be established if this study mirrors
clinical CHF, our findings may represent an important
mechanism for the endothelial dysfunction and raised
peripheral resistance associated with CHF.
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